Relationship between single oral dose pharmacokinetics of alprazolam and triazolam

International Clinical Psychopharmacology

Volumn 12, Issue 3, 1997, Pages 153-157

  Otani, K ^a   Yasui, N ^a   Furukori, H ^a   Kaneko, S ^a   Tasaki, H ^a   Ohkubo, T ^a   Nagasaki, T ^b   Sugawara, K ^a   Hayashi, K ^c  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Goshogawara City Hospital   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Alprazolam; Pharmacokinetics; Single oral dose; Triazolam

Indexed keywords

ALPRAZOLAM; TRIAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOLUNTEER;

EID: 0030741716     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705000-00006     Document Type: Article

References (19)

1. Bock KW, Schrenk D, Forster A, Griese E-U, Morike K, Brockmeier D and Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics, 4, 209-228.
2. Fleishaker JC and Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. European Journal of Clinical Pharmacology, 46, 35-39.
3. Garzone PD and Kroboth PD (1989) Pharmacokinetics of newer benzodiazepines. Clinical Pharmacokinetics, 16, 337-364.
4. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA and Shader RI (1991) Sensitivity to triazolam in the elderly. New England Journal of Medicine, 324, 1691-1698.
5. Greenblatt DJ and Wright CE (1993) Clinical pharmacokinetics of alprazolam: therapeutic implications. Clinical Pharmacokinetics, 24, 453-471.
6. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE and Brosen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology, 51, 73-78.
7. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 891-96.
8. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metabolism and Disposition, 22, 947-955.
9. Ochs HR, Greenblatt DJ and Burstein ES (1987) Lack of influence of cigarette smoking on triazolam pharmacokinetics. British Journal of Clinical Pharmacology, 23, 759-763.
10. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 53, 298-305.
11. Pakes GE, Brogden RN, Heel RC, Speight TM and Avery GS (1981) Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs, 22, 81-110.
12. Phillips JP, Antal EJ and Smith RB (1986) A pharmacokinetic drug interaction between erythromycin and triazolam. Journal of Clinical Psychopharmacology, 6, 297-299.
13. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics, 59, 491-502.
14. Varhe A, Olkkola KT and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or intraconazole. Clinical Pharmacology and Therapeutics, 56, 601-607.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS and Shader RI (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
16. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright E and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro; effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370-379.
17. Watkins PB (1994) Non-invasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171-184.
18. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K and Ishizaki T (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in-vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clinical Pharmacology and Therapeutics, 59, 514-519.
19. Zar JH (1996) Biostatistical Analysis, 3rd edn. Prentice-Hall, Upper Saddle River, NJ.